Chemistry:Dacetuzumab

From HandWiki
Revision as of 03:34, 6 February 2024 by JStaso (talk | contribs) (simplify)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Monoclonal antibody
Dacetuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD40
Clinical data
Other namesSGN-40
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6452H9964N1732O1998S42
Molar mass145111.33 g·mol−1
 ☒N☑Y (what is this?)  (verify)

Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody[1] being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma[2] and hematological malignancies.[3]

This drug was developed by Seattle Genetics, Inc.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab, American Medical Association.
  2. "Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma". Journal of Clinical Oncology 27 (26): 4371–7. September 2009. doi:10.1200/JCO.2008.21.3017. PMID 19636010. 
  3. "Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies". Current Opinion in Investigational Drugs 10 (6): 579–87. June 2009. PMID 19513947.